Appearance of cellular and humoral immunity in guinea pigs after infection with Coxiella burnetii administered in small-particle aerosols

Vaccines prepared from Formalin-killed whole cells of Coxiella burnetii (Ohio strain) or from chloroform-methanol residue (CMR) and extract (CME) of such cells were examined for biological and immunological properties in male C57BL/10ScN endotoxin nonresponder mice. Vaccines containing killed whole cells induced a high incidence of gross pathology, as evidenced by liver necrosis, significant splenomegaly, and significant hepatomegaly in mice. The degree and onset of these pathological changes were directly and inversely proportional, respectively, to the dosage of killed organisms administered. Conversely, no splenomegaly, hepatomegaly, or liver necrosis were observed in mice inoculated with CMR or CME. Moreover, killed whole cells were lethal for mice at dosages of 150 to 1,200 micrograms, whereas no deaths were seen in animals given 1,200 micrograms of CMR. In addition, antibodies against phase I and phase II antigens of C. burnetii were detected in the sera of mice inoculated with either whole cells or CMR. Enhanced blastogenic response of splenic lymphocytes was observed when animals were vaccinated with killed whole cells and CMR but not with CME. Moreover, 80 to 90% of mice inoculated with 300 micrograms of the CMR were protected against a lethal challenge of viable rickettsiae, whereas only 50% of the animals given 300 micrograms of killed whole cells were protected. Treatments with CME were essentially without value, since no antibodies were detectable and no significant protection was elicited. Collectively, these results show that, although killed whole cells induced immunity in C57BL/10ScN mice, they induced deleterious tissue reactions, whereas CMR, which also induced immunity, was essentially nondeleterious, based on the parameters employed. These observations suggest that the chloroform-methanol-extractable component(s) is implicated in the deleterious tissue reactions and that the phase I and II antigens may not be involved in the induction of the pathology observed in C57BL/10ScN mice.

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice

Williams¹,

Cantrell²

1982

“…The guinea pig has been used extensively as an experimental model for C. burnetii infections (9,17,21,22,30) and is still the model system of choice for the initial evaluation of Q-fever vaccines. The pathogenesis of the Nine Mile strain has been examined in some detail (15).…”

Section: Discussionmentioning

confidence: 99%

Comparative virulence of intra- and interstrain lipopolysaccharide variants of Coxiella burnetii in the guinea pig model

Moos¹,

Hackstadt²

1987

194

112

We compared the relative infectivity and virulence of lipopolysaccharide (LPS) variants of the Nine Mile strain of Coxiella burnetii with those of the Priscilla strain, a representative of endocarditis-type strains. In agreement with results of previous studies, Nine Mile phase I (9mi/I) organisms were highly infectious, eliciting seroconversion and fever with inocula containing as few as four organisms. Viable 9mi/I was recovered from the spleens of infected animals 30 days postinfection. Nine Mile phase II (9mi/II) organisms did not elicit fever or seroconversion except with very large inocula, and viable organisms could not be recovered at 30 days postinfection. The Nine Mile/Crazy variant, bearing the intermediate-type LPS, was also highly infectious, as determined by fever response and seroconversion, although, as with 9mi/II, viable organisms could not be recovered 30 days postinfection. The Priscilla strain in phase I (Pris/I) was as infectious as 9mi/I, as determined by seroconversion and its presence in the spleen 30 days postinfection; but in contrast to 9mi/I, more than 105 Pris/I isolates were required to induce fever. The temporal appearances of anti-phase I and II antibodies were similar for the two strains. A variety of serological techniques measuring antibody response against whole-cell and purified LPS antigens in agglutination, immunofluorescence, enzyme-linked immunosorbent, and immunoblot assays did not demonstrate sufficient specificity to distinguish between 9mi/I and Pris/I infections. Results of vaccine cross-challenge experiments showed a significant degree of protection between homologous and heterologous challenge strains.

“…It is known that phase II cells are much less effective vaccines than are phase I cells (22). Roles for both antibody (16) and cellmediated immunity (15,18) as protective mechanisms in Q fever have been proposed. Although the accessibility of surface components to T-cell recognition sites was not examined here, it seems likely that if antibody cannot reach the surfaces of the microbes, neither would immune cells be able to contact C. burnetii surface proteins.…”

Section: Discussionmentioning

confidence: 99%

Steric hindrance of antibody binding to surface proteins of Coxiella burnetti by phase I lipopolysaccharide

Hackstadt

1988

The exposure of surface protein antigens on virulent phase I Coxiella burnetti was compared with that on avirulent phase II cells. Although anti-phase II antibodies did not bind to the surfaces of native intact phase I cells, they bound to phase I proteins if the proteins were solubilized for sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by immunoblotting. In addition, removal of the phase I lipopolysaccharide (LPS) by trichloroacetic acid exposed surface proteins for reactivity with anti-phase II antibodies, as shown by immunofluorescence assays, direct antibody binding, and immunoelectron microscopy using protein A-colloidal gold conjugates. Based on these observations, a simple model of phase variation is proposed to explain the apparently conflicting notions of the identity of the phase II antigen(s). The model suggests that the phase I LPS sterically hinders access of anti-phase II antibodies to a multitude of shared protein antigens, any one of which may confer phase II specificity. Exposure of these shared protein antigens through the appearance of a more truncated LPS (phase II) or extraction of the smooth-type phase I LPS allows antibody accessibility and therefore confers apparent phase II serospecificity.